38wt: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
Created page with "'''Unreleased structure''' The entry 38wt is ON HOLD Authors: Nie, Z., Madden, D.R. Description: Crystal structure of the CFTR inhibitory factor Cif with the L174A mutation Category: Unreleased Structures Category: Nie, Z Category: Madden, D.R"
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
'''Unreleased structure'''


The entry 38wt is ON HOLD
==Crystal structure of the CFTR inhibitory factor Cif with the L174A mutation==
 
<StructureSection load='38wt' size='340' side='right'caption='[[38wt]], [[Resolution|resolution]] 1.52&Aring;' scene=''>
Authors: Nie, Z., Madden, D.R.
== Structural highlights ==
 
<table><tr><td colspan='2'>[[38wt]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Pseudomonas_aeruginosa_UCBPP-PA14 Pseudomonas aeruginosa UCBPP-PA14]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=38WT OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=38WT FirstGlance]. <br>
Description: Crystal structure of the CFTR inhibitory factor Cif with the L174A mutation
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.52&#8491;</td></tr>
[[Category: Unreleased Structures]]
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene></td></tr>
[[Category: Nie, Z]]
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=38wt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=38wt OCA], [https://pdbe.org/38wt PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=38wt RCSB], [https://www.ebi.ac.uk/pdbsum/38wt PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=38wt ProSAT]</span></td></tr>
[[Category: Madden, D.R]]
</table>
== Function ==
[https://www.uniprot.org/uniprot/CIF_PSEAB CIF_PSEAB] Virulence factor that impairs the host airway defenses and may play an important role in the early colonization of the lung (PubMed:18458065, PubMed:20118260, PubMed:28982736). It decreases mucociliary transport and hinders bacterial clearance from the lung, likely increasing the severity or duration of the infection (PubMed:28982736). Cif decreases the apical membrane abundance of host cystic fibrosis transmembrane conductance regulator (CFTR), which plays an important role in airway mucociliary defense, and reduces the CFTR-mediated chloride ion secretion in human airway epithelial cells and kidney cells (PubMed:17502391, PubMed:21455491). It alters the intracellular trafficking of CFTR, and redirects CFTR from recycling endosomes to the lysosomal degradative pathway (PubMed:21455491). Cif acts by enhancing the interaction of the host cell deubiquitinating enzyme USP10 with the Ras GTPase-activating protein-binding protein 1 (G3BP1), which inhibits the ability of USP10 to interact with, and deubiquitinate CFTR (PubMed:21455491). Inactivation of USP10 facilitates the lysosome-mediated degradation of the CFTR secretory chloride channel, which reduces mucociliary clearance of respiratory pathogens by human airway epithelial cells (PubMed:21455491). It reduces mucociliary transport (MCT) in vitro and the clearance of P.aeruginosa from the host in vivo (PubMed:28982736). Cif also reduces the apical membrane abundance of the host ATP-dependent translocase ABCB1 (P-glycoprotein 1, MDR1) in kidney, intestine and airway epithelial cells (PubMed:18650266). In addition, it reduces the protein abundance of the antigen peptide transporter 1 (TAP1), but not protein abundance of TAP2 (PubMed:24247241). Reducing USP10 deubiquitinating activity leads to increased ubiquitination and proteasomal degradation of TAP1, which reduces TAP-mediated transport of peptides into the endoplasmic reticulum and subsequent MHC class I-mediated viral and bacterial antigen presentation at the host cell surface (PubMed:24247241). Retrograde trafficking of Cif to the endoplasmic reticulum is required for the Cif-mediated reduction in TAP1 (PubMed:24247241). In contrast, Cif has no effect on the membrane abundance of some other ABC transporters such as ABCC1 (MRP1) and ABCC2 (MRP2) (PubMed:18650266).<ref>PMID:17502391</ref> <ref>PMID:18458065</ref> <ref>PMID:18650266</ref> <ref>PMID:20118260</ref> <ref>PMID:21455491</ref> <ref>PMID:24247241</ref> <ref>PMID:28982736</ref>  Cif shows epoxide hydrolase activity (PubMed:17502391, PubMed:18458065, PubMed:20118260, PubMed:21933119, PubMed:26136396, PubMed:26752215, PubMed:27980032, PubMed:28392259). The host epithelial-derived 14,15-epoxyeicosatrienoic acid (14,15-EET) was identified as an endogenous substrate (PubMed:27980032). 14,15-EET plays a particularly critical role as a paracrine stimulus for the production by neutrophils of the proresolving lipid mediator 15-epi LXA(4), which plays a critical role in limiting neutrophil activation and tissue inflammation (PubMed:27980032). Cif hydrolyzes 14,15-EET produced in response to inflammation into its cognate diol, indirectly eliminating the production of the proresolving lipid 15-epi LXA(4) by host neutrophils, which promotes sustained airway inflammation (PubMed:27980032). The epoxide hydrolase activity of Cif is also strictly required for its effects on CFTR, suggesting the existence of an epoxide signal involved in the deubiquitination and post-endocytic recycling of CFTR (PubMed:20118260, PubMed:26136396). The active site can accommodate a range of potential physiological epoxide substrates, suggesting that Cif can target and perturb key host immune signals (PubMed:28392259). It can degrade in vitro the xenobiotic substrate epoxide epibromohydrin (EBH) to its vicinal diol, 3-bromo-1,2-propanediol (PubMed:18458065, PubMed:20118260, PubMed:21933119, PubMed:26136396, PubMed:26752215). It also acts on the epoxide hydrolase synthetic substrate (S)-NEPC in a concentration-dependent manner (PubMed:17502391). Also shows activity against cis-stilbene oxide (CSO) (PubMed:20118260). Does not exhibit haloacetate dehalogenase (HAD) or haloalkane dehalogenase (HLD) activity against standard substrates (PubMed:20118260).<ref>PMID:17502391</ref> <ref>PMID:18458065</ref> <ref>PMID:20118260</ref> <ref>PMID:21933119</ref> <ref>PMID:26136396</ref> <ref>PMID:26752215</ref> <ref>PMID:27980032</ref> <ref>PMID:28392259</ref>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Large Structures]]
[[Category: Pseudomonas aeruginosa UCBPP-PA14]]
[[Category: Madden DR]]
[[Category: Nie Z]]

Revision as of 06:59, 7 October 2026

Crystal structure of the CFTR inhibitory factor Cif with the L174A mutation

38wt, resolution 1.52Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA